Here is the latest news and forecast for Ocugen Inc(OCGN)

Key Points

– In February, the company struck a deal with Bharat Biotech to manufacture the Covaxin coronavirus vaccine, which was recently shown to be 81% effective in a phase 3 clinical trial in India. Ocugen’s agreement specifies that it will manufacture and sell the vaccine in the U.S. while profiting 45% from every sale.
– If Covaxin receives Regulatory approval in the United States later this year, Ocugen will have a major revenue stream.

Market Data

Ocugen Inc(OCGN) is a stock of interest due to the large impact the company has on the market. Here at Wall Street Facts we only cover the best stocks so make sure you check out our other articles. Today we will be diving deep into all of the essential information you need to know about OCGN. We will be studying the movement so you can make the best decision as an investor. The stock has moved downwards today by 0.22%. The high for today is 6.80 and today’s low is 6.51. This information is critical in deciding whether this investment is risky or not. We can see the stock is trending downwards, which means the volume of people selling this stock is greater than people buying it.

Company Description

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, OCU200, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.

Stock Forecast

As an investor, you can get an idea of where the stock is trending by the forecast. In this case, the high forecast for Ocugen Inc is $15.00 and the low forecast is $10.00. We can get a look into the future by looking at past trends. Looking at Ocugen Inc’s 5-year movement it seems it has fallen 95%. Overall, Ocugen Inc is in great shape going forward. They have a strong market cap of $1.26B and a very bright future ahead of them.

Leave a Reply

%d bloggers like this: